Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat in Refractory CLL
NCT00431873Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jan 2007
- Primary completion
- Nov 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of mocetinostat in chronic lymphocytic leukemia (CLL), sponsored by Mirati Therapeutics. Primary endpoint: Response Rate at 1 year. Started Jan 2007; status: completed.
02
Drugs
mocetinostat
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00431873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431873.